Skip to content

Kodiak Sciences

US · KOD #1934 by market cap Listed 2018
97.17 -0.73 -0.75%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:57

Valuation each multiple against its own 5-year range

P/B ratio 579.11 Expensive vs history 100th percentile
5-year average 12.06 · #514 of 514 in Biotechnology
P/E ratio -27.25 Cheap vs history 0th percentile
5-year average -3.86 · forward -27.33
P/S ratio --
5-year average 0.00 · forward 379.55

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Kodiak Sciences (KOD) 6.35B -23.82 506.09 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value97.51 Economic moatNone UncertaintyVery High

Trading 0.3% below Morningstar's fair value estimate.

Fair value

Kodiak Sciences Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 14% premium over our quantitative fair value estimate of $97.51 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.

The firm's valuation metrics undermine our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 1.0%, which ranks in the bottom 10% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are overvalued.

The firm's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -3.3%, a core component of profitability, falls in the bottom 20% globally. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:57:11 · For reference only, not investment advice and not tailored to your situation.

Kodiak Sciences discussion 0 comments

Add a comment